Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3583-3590

  Luftner D ^a,d   Wagner, K ^a   Dingeldein, G ^a   Haas, A ^b   Sezer, O ^a   Mergenthaler, H G ^c   Wernecke, K D ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM ERNST VON BERGMANN   (Germany)

^c Innere Medizin/Endokrinologie   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Adjuvant high dose chemotherapy; Breast cancer; Epirubicin; Ifosfamide

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CD34 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; VINDESINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE METASTASIS; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; PAIN; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; TIME FACTORS; VINCRISTINE;

EID: 0343550534     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Somlo G, Doroshow JH, Forman S et al: High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 15: 2882-2893, 1997.
2. de Graaf H, Willemse PH, de Vries EG et al: Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 2: 150-153, 1994.
3. Garcia-Carbonero R, Hidalgo M, Paz-Ares L et al: Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 15: 3178-3184, 1997.
4. Peters WP, Ross M, Vredenburgh JJ et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132-1143, 1993.
5. Buzzoni R, Bonadonna G, Valagussa P et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9: 2134-2140, 1991.
6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71-84, 1992.
7. Gad el Mawla N: Use of ifosfamide in the management of breast cancer. Ann Oncol 3 (Suppl 3): 21-23, 1992.
8. 2 ifosfamide with Mesna as second- or third-line therapy in advanced breast cancer. Cancer Chemother Pharmacol 26: 63-65, 1990.
9. Ghavamzadeh A. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 26: 66-88, 1990.
10. Schmid H, Kaufmann M, Grischke E et al: Ifosfamide combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 26 (Suppl): S 71-S 73, 1990.
11. Hoffmann W, Weidmann B, Migeod F et al: Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer Chemother Pharmacol 26: 69-70, 1990.
12. Lange OF, Scheef W, Haase KD et al: Palliative chemoradiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial. Cancer Chemother Pharmacol 26: 74-77, 1990.
13. Manegold C, Worst P, Bickel J et al: Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. Cancer Chemother Pharmacol 26: 87-90, 1990.
14. Gad el Mawla N, Hamza MR, Zikri ZK et al: Ifosfamide, methotrexate, and 5-fluorouracil: Effective combination in resistant breast cancer. Cancer Chemother Pharmacol 26: 85-86, 1990.
15. Sanchiz F, Milla A. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study. Cancer Chemother Pharmacol 26: 91-92, 1990.
16. Langenbuch T, Mross K, Jonat W et al: A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 26: 93-96, 1990.
17. WHO handbook for reporting results of cancer treatment. WHO offset publications. Geneva 48, 1979.
18. Tomás JF, Pérez-Carrión R, Escudero A et al: Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 19: 331-336, 1996.
19. Gianni AM, Siena S, Bregni M et al: 5-year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Proc ASCO 14: 90, 1995.
20. Abeloff MD, Beveridge RA, Donehower RC et al: Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 82: 570-574, 1990.
21. Peters WP, Berry D, Vredenburgh JJ et al: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥10 axillary lymph nodes (DUKE/CALGB 8782). Proc ASCO 14: 317, 1995.
22. Overmoyer B, Dannley R, Goormastic M et al: Consolidation for high risk breast cancer with high dose chemotherapy and autologous bone marrow rescue. Proc ASCO 13: 93, 1994.
23. Jennis A, Pecora AL, Rosenbluth R et al: Phase II trial of sequential non-cross resistant chemotherapy with autologous blood stem cell support in stage II-IIIa breast cancer with 10 or more involved axillary nodes. Proc ASCO 17: 149a, 1998.
24. Lluch A, Azagra P, Solano C et al: A case-control study of adjuvant high dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) transplantation or conventional chemotherapy (CT) in operable breast cancer (BC) patients (PTS) with 10 or more involved nodes. Proc ASCO 17: 155a, 1998.
25. 2, followed by consolidation with high-dose chemotherapy (HDC) and autologous peripheral stem cell support (APSCS). Proc ASCO 17: 176a, 1998.
26. Buzdar AU, Kau SW, Hortobagyi GN et al: Clinical course of patients with breast cancer with ten or more involved positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69: 448-52, 1992.
27. Cocconi G, Algeri R, Contu A et al: Randomized trial of conventional vs a more intensive sequential chemotherapy as adjuvant treatments in stage II breast carcinoma with ≥10 involved axillary nodes, Proc ASCO 13: 62, 1994.
28. Fumoleau P, Chauvin F, Namer M et al: Three-year follow-up results of adjuvant chemotherapy with AC versus high-dose mitoxantrone, cyclophosphamide (MC) with filgrastim in operable breast cancer involving 10 or more axillary lymph nodes. Proc ASCO 16: 143a, 1997.
29. Demetri GD, Berry D, Norton L et al: Clinical outcomes of node-positive breast cancer patients treated with dose-intensified Adriamycin/cyclophosphamide (AC) followed by taxol (T) as adjuvant systemic chemotherapy (CALGB 9141). Proc ASCO 16: 143a, 1997.
30. Bisagni G, Cocconi G, Algeri R et al: CMF vs a sequential cisplatin/anthracycline containing regimen as adjuvant chemotherapy (CT) in stage II breast carcinoma (BC) with ≥10 involved axillary nodes. A prospective randomized study. Proc ASCO 17: 116a, 1998.
31. Hortobagyi GN, Buzdar AU, Champlin R et al: Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer - A randomised trial. Proc ASCO 17: 123a, 1998.
32. Rodenhuis S, Richel DJ, van der Wall E et al: Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515-21, 1998.